MASLD has emerged as the leading cause of chronic liver disease, affecting one in four people globally and up to 40% of adults in the United States.1 It is the leading cause of cirrhosis and liver transplantation in women. As new therapies advance, early identification, risk stratification, and intervention are essential to slowing disease progression and improving patient outcomes.

Data from reference 1

This is where OWLiver® plays a critical role. As the only non-invasive test capable of identifying all treatable stages of MASLD, OWLiver helps clinicians, payors, and patients make better, more timely decisions to improve overall liver health.1

Actionable Insight Without Invasive Procedures

For clinicians, OWLiver offers a clinically meaningful alternative to invasive procedures such as liver biopsy. Through a simple blood draw, providers gain:

  • Early and accurate detection of MASLD/MASH across all stages
  • Clear, actionable insights to guide diagnosis and management
  • Identification of patients most likely to benefit from emerging pharmacological therapies, such as GLP-1s

By enabling earlier intervention and more informed treatment decisions, OWLiver helps clinicians optimize outcomes while streamlining care – and OwLiver has an established reimbursement pathway.

Better Targeting Means Lower Long-Term Costs

MASLD/MASH progression drives significant downstream costs, including hospitalizations, advanced imaging, and invasive diagnostics. OWLiver® supports a value-based care model by:

  • Detecting disease earlier before costly complications arise
  • Reducing reliance on expensive and invasive procedures
  • Identifying appropriate candidates for therapy, improving treatment efficiency
  • Supporting monitoring strategies that help prevent disease escalation

By aligning treatment with disease biology, OWLiver helps lower overall healthcare costs while improving care quality.

Clarity and Confidence for Patients

OWLiver represents more than a diagnostic test for patients. It helps them easily understand their liver health and feel confident in their treatment.

A simple blood test provides:

  • Early detection of liver disease
  • Ongoing insight into disease progression
  • Greater understanding of treatment impact
  • Increased engagement in long-term liver health management

With clearer information and fewer invasive procedures, patients are better equipped to take proactive steps toward managing their condition.

Supporting the Next Era of MASLD/MASH Care

As new therapies reshape the MASLD/MASH treatment landscape, OWLiver plays a critical role in ensuring the right patients receive the right intervention at the right time. By combining early detection, dynamic monitoring, and actionable insights, OWLiver can help improve outcomes while supporting more efficient, cost-effective care.

To learn more, contact us at https://cimasciences.com/contact/

REFERENCES

1 Estes, C, Razavi, H, Loomba, R, Younossi, Z and Sanyal, AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018 Jan;67(1):123-133. DOI:10.1002/hep.29466.